Innate Pharma to hold its Annual General Meeting of Shareholders on May 22,...
Marseille, France, May 1, 2019, 7:00 AM CESTInnate Pharma (the “Company” - Euronext Paris: FR0010331421 – IPH) will hold its Annual General Meeting of Shareholders (“AG..
View ArticleInnate Pharma First Quarter 2019 Report
Cash, cash equivalents and financial assets of the Company amounted to €237.1 million[*]Initiation of cohort expansion study of mo..
View ArticleOutcome of Annual General Meeting of May 22, 2019
Marseille, France, May 23, 2019, 7:00 AM CESTInnate Pharma (Euronext Paris: FR0010331421 – IPH) announces the results of the voting by shareholders at the Annual General Meeting (“AGM”) which took...
View ArticleINNATE PHARMA ANNOUNCES PUBLICATION ON NEXT GENERATION IMMUNOTHERAPIES...
The production of adenosine via CD39 and CD73 enzymes participates in an immunosuppressive tumor microenvironment.
View ArticleInnate Pharma announces publication in Cell on innovative multifunctional...
The findings describe potential first-in-class NKp46 NKCEs, a new generation of multifunctional antibody-based molecules for fighting cancer
View ArticleInnate Pharma enrolls first patient in IPH4102 TELLOMAK Phase II study
INNATE PHARMA ENROLLS FIRST PATIENT IN IPH4102 TELLOMAK PHASE II STUDY TELLOMAK is a Phase II study to evaluate the efficacy of IPH4102 in different subtypes of T-cell lymphom..
View ArticleInnate Pharma to present IPH4102 “TELLOMAK” clinical trial design and...
Multicohort, multi-center, international Phase II study to evaluate the efficacy and safety of IPH4102 in patients with advanced T-cell lymphoma is ongoing
View ArticleInnate Pharma announces intention to conduct a registered offering in the...
INNATE PHARMA ANNOUNCES INTENTION TO CONDUCT A REGISTERED OFFERING IN THE UNITED STATESMarseille,France,
View ArticleInnate Pharma to host key opinion leader call on IPH4102 “TELLOMAK” clinical...
INNATE PHARMA TO HOST KEY OPINION LEADER CALL ON IPH4102 “TELLOMAK” CLINICAL TRIAL DESIGN AND RATIONALE Marseille, France, June 2..
View ArticleInnate Pharma announces publication of IPH4102 Phase I clinical trial results...
INNATE PHARMA ANNOUNCES PUBLICATION OF IPH4102 PHASE I CLINICAL TRIAL RESULTS FOR CTCL IN THE LANCET ONCOLOGY ·Data to date demonstrate high activity and favorable safety profile in Sézary...
View Article
